Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in children with polyarticular juvenile rheumatoid arthritis
2011-001661-40Phase 3
- Sponsor
- Abbott Laboratories
- Start
- Feb 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in polyarticular juvenile idiopathic arthritis (4 arms), sponsored by Abbott Laboratories. Primary endpoint: Disease flare during the double-blind phase in the non-methotrexate stratum.
02
Drugs
03
Conditions
polyarticular juvenile idiopathic arthritis
Beyond the preview
Go deeper on 2011-001661-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001661-40.